Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005848 · ClinicalTrials.gov registry record · Phase 2
R115777 in Treating Patients With Progressive, Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
A Phase 2 study, sponsored by Fox Chase Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT00005848 is a Phase 2 study that has completed, run by Fox Chase Cancer Center. The registered enrollment target is 7 participants.
The verdict
NCT00005848, a Phase 2 study, has completed, sponsored by Fox Chase Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of R115777 in treating patients who have progressive, metastatic prostate cancer that has not responded to hormone therapy.
Interventions
- DRUG chemotherapy
- DRUG tipifarnib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2000-04 |
| Est. Completion | 2007-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005848
The ClinicalTrials.gov registry entry for NCT00005848 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fox Chase Cancer Center, which has 183 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which chemotherapy is the first listed.
NCT00005848 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00005848 about?
NCT00005848 is a clinical study titled "R115777 in Treating Patients With Progressive, Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of R115777 in treating patients who have progressive, metastatic prostate cancer that has not responded to hormone therapy.
What is the current status of trial NCT00005848?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2000-04. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00005848?
The interventions under investigation include: chemotherapy (DRUG), tipifarnib (DRUG).
Who is sponsoring clinical trial NCT00005848?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.